arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Verrica Pharmaceuticals Inc.

VRCA
$4.74 ▲ +0.22 (+4.76%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Verrica Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $101.0M
Dividend Yield
Revenue Growth -53.8%
Op. Margin -223.4%
ROIC -240.2%
FCF / Share $-0.44
Trailing P/E
Price / Book 18.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.86M
↓ -53.8%
Net Income Profit after all expenses
$-9.68M
↑ +0.6%
Operating Margin Operating profit as % of sales
-223.4%
↓ -15.5% 7th
FCF / Share Free cash flow per share
$-0.44
↓ -1.3%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
12
Financial Health
69
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters